The FDA recently approved new COVID-19 vaccines for Americans, but due to certain restrictions, there has been mounting confusion on what they are, how much protection they’ll offer and whether ...

The U.S. Food and Drug Administration approved 2025-26 COVID-19 vaccines for anyone age 65 and older and any person 6 months and older who has at least one underlying health condition that increases ...

A week of fast-moving developments has left some with questions about access to the COVID-19 vaccine. While experts and officials say the new federal guidance surrounding COVID vaccine authorization ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. With the first strain of the coronavirus identified over five years ago ...

Learn the latest CDC COVID vaccine recommendations for 2025. Find out why updated shots matter for adults 65+, their safety, timing, and how they reduce severe illness and long COVID. On Sept. 19, ...

You’re not imagining it: The rollout of COVID-19 vaccines in 2025 has not been like previous years. But the big thing to know is that despite initial restrictions, California has now opened up access ...

ROCHESTER — As autumn approaches, updated COVID-19 vaccines, along with their annual influenza counterparts, are becoming available. For fall and winter 2025, "immunizations are an effective tool to ...

Data in this new study shows that the 2024–2025 COVID-19 vaccines provide similar protection to the previous formulation. They were found to be most protective four weeks after vaccination, providing ...

An internal FDA memo released by a Senate investigative panel found no pediatric deaths definitively linked to COVID-19 ...

Ron Johnson (R-Wis.) released the FDA analysis on pediatric deaths tied to COVID shots that was touted by former FDA ...

The CDC has issued updated recommendations for the 2025–2026 COVID-19 vaccination season, covering mRNA and protein subunit vaccines for people aged 6 months and older. The new formulations target ...

Naturally, the longer that symptoms persist, the higher the total cost. The previously mentioned $8 billion burden for 2025-2027 assumed the 6% incidence of long COVID with sympto ...